FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

RITIES AND EXCHANGE COMMISS	SION
-----------------------------	------

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

0.5

hours per response:

	Check this box if no longer subject to
	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Estepan Ian Michael</u>						2. Issuer Name and Ticker or Trading Symbol								5. Relationship of Reporting Person(s) to Issuer						
						Sar	Sarepta Therapeutics, Inc. [SRPT]										applicable) rector		10% Owner	
															1	Office			Other (s	specify
(Last) (First) (Middle) 215 FIRST STREET SUITE 415							3. Date of Earliest Transaction (Month/Day/Year) 08/30/2024									Chief Financial Officer				
(Street) CAMBRIDGE MA 02142					4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Line) Form filed by One Reporting Per Form filed by More than One Reperson										orting Pers	on				
(City)		(Stat	e) (Z	Zip)																
			Table	I - No	n-Deriva	tive S	Secu	rities	Acc	quired	l, Dis	posed of	, or B	Benefi	cially	Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/						Execution Da		ate,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										Code	v	Amount	(A) o (D)	r Pric	e	Transa	Transaction(s) (Instr. 3 and 4)			(111341. 4)
Common Stock 08/30/20)24			S		5,985(1)	D	\$13	37.36	33,946			D	
			Tat	ole II								osed of, convertib				Owne	d		,	
1. Title of Derivative Security (Instr. 3) 2. Conver or Exer Price of Derivat Securit		on se	3. Transaction Date (Month/Day/Year)	if any	emed tion Date, n/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expira (Month	tion Da		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Der Sed (Ins	Price of cirvative derivative str. 5) Security Beneficia Owned Following Reported Transacti (Instr. 4)		y G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownersh (Instr. 4)
						Code	ode V (A) (D)		Date Exercisable		Expiration Date	Title	Amour or Number of Shares	er						

Explanation of Responses:

1. Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards and other compensation.

/s/ Ryan Brown, as Attorney-09/03/2024 in-Fact for Ian Estepan

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.